The epithelial-to-mesenchymal transition in breast cancer: Focus on basal-like carcinomas

Cancers

Volumn 9, Issue 10, 2017, Pages

  Fedele, Monica ^a   Cerchia, Laura ^a   Chiappetta, Gennaro ^b  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Differentiation therapy; EMT; Exosomes; miRNAs; Molecular signaling; TNBC; Tumor plasticity; v 3

Indexed keywords

EID: 85031026363     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers9100134     Document Type: Review

References (150)

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase 2014, 11. ISBN-13 978-92-832-2447-1. IARC. Available online: http://publications.iarc.fr/Databases/Iarc-Cancerbases/Globocan-2012-Estimated-Cancer-Incidence- Mortality-And-Prevalence-Worldwide-In-2012-V1-0-2012 (accessed on 29 September 2017).
2. Kast, K., Link, T., Friedrich, K., Petzold, A., Niedostatek, A., Schoffer, O., Werner, C., Klug, S.J., Werner, A., Gatzweiler, A., et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res. Treat. 2015, 150, 621–629.
3. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750–2767.
4. Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A., Savage, M.I., Osborne, C.K., Hilsenbeck, S.G., Chang, J.C., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 2015, 21, 1688–1698.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70.
6. Prat, A., Parker, J.S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J.I., He, X., Perou, C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12, R68.
7. Prat, A., Perou, C.M. Mammary development meets cancer genomics. Nat. Med. 2009, 15, 842–844.
8. Felipe Lima, J., Nofech-Mozes, S., Bayani, J., Bartlett, J.M. EMT in breast carcinoma-A review. J. Clin. Med. 2016, 5, 65.
9. Mani, S.A., Guo, W., Liao, M., Eaton, E.N., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Campbell, L.L., Polyak, K., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715.
10. Morel, A.P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3, e2888.
11. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983–3988.
12. Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105–111.
13. Moreno-Bueno, G., Portillo, F., Cano, A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27, 6958–6969.
14. Ye, X., Brabletz, T., Kang, Y., Longmore, G.D., Nieto, M.A., Stanger, B.Z., Yang, J., Weinberg, R.A. Upholding a role for EMT in breast cancer metastasis. Nature 2017, 547, E1–E3.
15. Fisher, K.R., Altorki, N.K., Mittal, V., Gao, D. Fisher et al. replay. Nature 2017, 547, E5–E6.
16. Hennessy, B.T., Giordano, S., Broglio, K., Duan, Z., Trent, J., Buchholz, T.A., Babiera, G., Hortobagyi, G.N., Valero, V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann. Oncol. 2006, 17, 605–613.
17. Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K., Gilcrease, M.Z., Krishnamurthy, S., Lee, J.S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69, 4116–4124.
18. Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., Zhuang, Q., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7, 51–63.
19. Samavarchi-Tehrani, P., Golipour, A., David, L., Sung, H.K., Beyer, T.A., Datti, A., Woltjen, K., Nagy, A., Wrana, J.L. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010, 7, 64–77.
20. Takaishi, M., Tarutani, M., Takeda, J., Sano, S. Mesenchymal to epithelial transition induced by reprogramming factors attenuates the malignancy of cancer cells. PLoS ONE 2016, 11, e0156904.
21. Yao, D., Dai, C., Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 2011, 9, 1608–1620.
22. Micalizzi, D.S., Christensen, K.L., Jedlicka, P., Coletta, R.D., Barón, A.E., Harrell, J.C., Horwitz, K.B., Billheimer, D., Heichman, K.A., Welm, A.L., et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J. Clin. Investig. 2009, 119, 2678–2690.
23. Scimeca, M., Antonacci, C., Colombo, D., Bonfiglio, R., Buonomo, O.C., Bonanno, E. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers. Tumour Biol. 2016, 37, 5427–5435.
24. Massagué, J. TGFβ in Cancer. Cell 2008, 134, 215–230.
25. Miettinen, P.J., Ebner, R., Lopez, A.R., Derynck, R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J. Cell Biol. 1994, 127, 2021–2036.
26. Massagué, J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1, 169–178.
27. Derynck, R., Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577–584.
28. Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.R., Zhang, Y., Wrana, J.L. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307, 1603–1609.
29. Perez-Moreno, M., Jamora, C., Fuchs, E. Sticky business: Orchestrating cellular signals at adherens junctions. Cell 2003, 112, 535–548.
30. Zavadil, J., Böttinger, E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24, 5764–5774.
31. Bhowmick, N.A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C.A., Engel, M.E., Arteaga, C.L., Moses, H.L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 2001, 12, 27–36.
32. Shen, X., Li, J., Hu, P.P., Waddell, D., Zhang, J., Wang, X.F. The activity of guanine exchange factor NET1 is essential for transforming growth factor-beta-mediated stress fiber formation. J. Biol. Chem. 2001, 276, 15362–15368.
33. Ridley, A.J., Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70, 389–399.
34. Fukata, M., Kaibuchi, K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat.Rev. Mol. Cell Biol. 2001, 2, 887–897.
35. Lehmann, K., Janda, E., Pierreux, C.E., Rytömaa, M., Schulze, A., McMahon, M., Hill, C.S., Beug, H., Downward, J. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells. Genes Dev. 2000, 14, 2610–2622.
36. Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., Grünert, S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. J. Cell Biol. 2002, 156, 299–313.
37. Zavadil, J., Cermak, L., Soto-Nieves, N., Böttinger, E.P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 2004, 23, 1155–1165.
38. Eger, A., Stockinger, A., Park, J., Langkopf, E., Mikula, M., Gotzmann, J., Mikulits, W., Beug, H., Foisner, R. Beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004, 23, 2672–2680.
39. Lamb, R., Ablett, M.P., Spence, K., Landberg, G., Sims, A.H., Clarke, R.B. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS ONE 2013, 8, e67811.
40. Yook, J.I., Li, X.Y., Ota, I., Hu, C., Kim, H.S., Kim, N.H., Cha, S.Y., Ryu, J.K., Choi, Y.J., Kim, J., et al. A Wnt-Axin2-3β cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 2006, 8, 1398–1406.
41. Conacci-Sorrell, M., Simcha, I., Ben-Yedidia, T., Blechman, J., Savagner, P., Ben-Ze’ev, A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: The roles of beta-catenin signaling, Slug, and MAPK. J. Cell Biol. 2003, 163, 847–857.
42. Howe, L.R., Watanabe, O., Leonard, J., Brown, A.M. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003, 63, 1906–1913.
43. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469–480.
44. Taelman, V.F., Dobrowolski, R., Plouhinec, J.L., Fuentealba, L.C., Vorwald, P.P., Gumper, I., Sabatini, D.D., De Robertis, E.M. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010, 143, 1136–1148.
45. Bhat, R.A., Stauffer, B., Komm, B.S., Bodine, P.V. Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. J. Cell. Biochem. 2007, 102, 1519–1528.
46. Niehrs, C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25, 7469–7481.
47. Suzuki, H., Toyota, M., Carraway, H., Gabrielson, E., Ohmura, T., Fujikane, T., Nishikawa, N., Sogabe, Y., Nojima, M., Sonoda, T., et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br. J. Cancer 2008, 98, 1147–1156.
48. Pohl, S.G., Brook, N., Agostino, M., Arfuso, F., Kumar, A.P., Dharmarajan, A. Wnt signaling in triple-negative breast cancer. Oncogenesis 2017, 6, e310.
49. Ishitani, T., Ninomiya-Tsuji, J., Matsumoto, K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol. Cell. Biol. 2003, 23, 1379–1389.
50. DiMeo, T.A., Anderson, K., Phadke, P., Fan, C., Perou, C.M., Naber, S., Kuperwasser, C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69, 5364–5373.
51. Xu, J., Prosperi, J.R., Choudhury, N., Olopade, O.I., Goss, K.H. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE 2015, 10, e0117097.
52. Borg, J.-P., Belotti, E., Daulat, A., Lembo, F., Bertucci, F., Charafe-Jauffret, E., Birnbaum, D. Deregulation of the non-canonical pathway in triple-negative breast cancer. FASEB J. 2013, 27.
53. Miele, L. Notch signaling. Clin. Cancer Res. 2006, 12, 1074–1079.
54. Leong, K.G., Karsan, A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006, 107, 2223–2233.
55. Weijzen, S., Rizzo, P., Braid, M., Vaishnav, R., Jonkheer, S.M., Zlobin, A., Osborne, B.A., Gottipati, S., Aster, J.C., Hahn, W.C., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8, 979–986.
56. Ayyanan, A., Civenni, G., Ciarloni, L., Morel, C., Mueller, N., Lefort, K., Mandinova, A., Raffoul, W., Fiche, M., Dotto, G.P., Brisken, C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 2006, 103, 3799–3804.
57. Guo, S., Liu, M., Gonzalez-Perez, R.R. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta 2011, 1815, 197–213.
58. Mittal, S., Sharma, A., Balaji, S.A., Gowda, M.C., Dighe, R.R., Kumar, R.V., Rangarajan, A. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: Novel therapeutic strategy for aggressive breast cancers. Mol. Cancer Ther. 2014, 13, 3198–3209.
59. Leong, K.G., Niessen, K., Kulic, I., Raouf, A., Eaves, C., Pollet, I., Karsan, A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J. Exp. Med. 2007, 204, 2935–2948.
60. Li, L., Zhao, F., Lu, J., Li, T., Yang, H., Wu, C., Liu, Y. Notch-1 signaling promotes the malignant features of human breast cancer through NF-αB activation. PLoS ONE 2014, 9, e95912.
61. Gallahan, D., Jhappan, C., Robinson, G., Hennighausen, L., Sharp, R., Kordon, E., Callahan, R., Merlino, G., Smith, G.H. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996, 56, 1775–1785.
62. Hu, C., Diévart, A., Lupien, M., Calvo, E., Tremblay, G., Jolicoeur, P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am. J. Pathol. 2006, 168, 973–990.
63. Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., Miele, L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16, 3141–3152.
64. Zhang, X., Liu, X., Luo, J., Xiao, W., Ye, X., Chen, M., Li, Y., Zhang, G.J. Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis 2016, 5, e269.
65. Harvey, K.F., Zhang, X., Thomas, D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13, 246–257.
66. Pegoraro, S., Ros, G., Ciani, Y., Sgarra, R., Piazza, S., Manfioletti, G. A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget 2015, 6, 19087–190101.
67. Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A.R., Poletti, A., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147, 759–772.
68. Overholtzer, M., Zhang, J., Smolen, G.A., Muir, B., Li, W., Sgroi, D.C., Deng, C.X., Brugge, J.S., Haber, D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA 2006, 103, 12405–12410.
69. Bartucci, M., Dattilo, R., Moriconi, C., Pagliuca, A., Mottolese, M., Federici, G., Benedetto, A.D., Todaro, M., Stassi, G., Sperati, F., et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2015, 34, 681–690.
70. Chen, D., Sun, Y., Wei, Y., Zhang, P., Rezaeian, A.H., Teruya-Feldstein, J., Gupta, S., Liang, H., Lin, H.K., Hung, M.C., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 2012, 18, 1511–1517.
71. Kim, N.G., Koh, E., Chen, X., Gumbiner, B.M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl. Acad. Sci. USA 2011, 108, 11930–11935.
72. Wang, Y., Liu, J., Ying, X., Lin, P.C., Zhou, B.P. Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway. Sci. Rep. 2016, 6, 24606.
73. Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M.P., Brabletz, T. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 2016, 7, 10498.
74. Salah, Z., Itzhaki, E., Aqeilan, R.I. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway. Oncotarget 2014, 5, 10886–10900.
75. Habib, J.G., O’Shaughnessy, J.A. The hedgehog pathway in triple-negative breast cancer. Cancer Med. 2016, 5, 2989–3006.
76. Jiang, J., Hui, C.C. Hedgehog Signaling in Development and Cancer. Dev. Cell 2008, 15, 801–812.
77. Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M., Kondoh, H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: Implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999, 126, 3915–3924.
78. Brennan, D., Chen, X., Cheng, L., Mahoney, M., Riobo, N.A. Noncanonical Hedgehog signaling. Vitam. Horm. 2012, 88, 55–72.
79. Lauth, M., Toftgård, R. Non-canonical activation of GLI transcription factors: Implications for targeted anti-cancer therapy. Cell Cycle 2007, 6, 2458–2463.
80. Colavito, S.A., Zou, M.R., Yan, Q., Nguyen, D.X., Stern, D.F. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFB) pathway. Breast Cancer Res. 2014, 16, 444.
81. Das, S., Samant, R.S., Shevde, L.A. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J. Biol. Chem. 2013, 288, 11824–11833.
82. Lei, J., Fan, L., Wei, G., Chen, X., Duan, W., Xu, Q., Sheng, W., Wang, K., Li, X. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol. 2015, 36, 3119–3126.
83. Fiaschi, M., Rozell, B., Bergström, A., Toftgård, R. Development of mammary tumors by conditional expression of GLI1. Cancer Res. 2009, 69, 4810–4817.
84. Gonzalez, D.M., Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 2014, 7, re8.
85. Gschwind, A., Fischer, O.M., Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 2004, 4, 361–370.
86. Gjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B.T., Micklem, D.R., Akslen, L.A., Glackin, C., Lorens, J.B. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 2010, 107, 1124–1129.
87. Schoumacher, M., Burbridge, M. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr. Oncol. Rep. 2017, 19, 19.
88. Lindsey, S., Langhans, S.A. Crosstalk of Oncogenic Signaling Pathways during Epithelial-Mesenchymal Transition. Front. Oncol. 2014, 4, 358.
89. Jechlinger, M., Sommer, A., Moriggl, R., Seither, P., Kraut, N., Capodiecci, P., Donovan, M., Cordon-Cardo, C., Beug, H., Grünert, S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. 2006, 116, 1561–1570.
90. Wagenblast, E., Soto, M., Gutiérrez-Ángel, S., Hartl, C.A., Gable, A.L., Maceli, A.R., Erard, N., Williams, A.M., Kim, S.Y., Dickopf, S., et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 2015, 520, 358–362.
91. Desgrosellier, J.S., Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9–22.
92. Camorani, S., Crescenzi, E., Gramanzini, M., Fedele, M., Zannetti, A., Cerchia, L. Aptamer-mediated impairment of EGFR-integrin avβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci. Rep. 2017, 7, 46659.
93. D'Ippolito, E., Plantamura, I., Bongiovanni, L., Casalini, P., Baroni, S., Piovan, C., Orlandi, R., Gualeni, A.V., Gloghini, A., Rossini, A., et al. miR-9 and miR-200 regulate pdgfrβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer. Cancer Res. 2016, 76, 5562–5572.
94. Seguin, L., Kato, S., Franovic, A., Camargo, M.F., Lesperance, J., Elliott, K.C., Yebra, M., Mielgo, A., Lowy, A.M., Husain, H., et al. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16, 457–468.
95. De Franceschi, N., Hamidi, H., Alanko, J., Sahgal, P., Ivaska, J. Integrin traffic-The update. J. Cell Sci. 2015, 128, 839–852.
96. Borges, E., Jan, Y., Ruoslahti, E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 2000, 275, 39867–39873.
97. Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.A., Delaloye, J.F., Huelsken, J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481, 85–89.
98. Radisky, E.S., Radisky, D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 5, 201–212.
99. Paltridge, J.L., Belle, L., Khew-Goodall, Y. The secretome in cancer progression. Biochim. Biophys. Acta 2013, 1834, 2233–2241.
100. Makridakis, M., Vlahou, A. Secretome proteomics for discovery of cancer biomarkers. J. Proteom. 2010, 73, 2291–2305.
101. Hanahan, D., Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21, 309–322.
102. Yu, Y., Xiao, C.H., Tan, L.D., Wang, Q.S., Li, X.Q., Feng, Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br. J. Cancer 2014, 110, 724–732.
103. Worthley, D.L., Si, Y., Quante, M., Churchill, M., Mukherjee, S., Wang, T.C. Bone marrow cells as precursors of the tumor stroma. Exp. Cell Res. 2013, 319, 1650–1656.
104. Barcellos-de-Souza, P., Gori, V., Bambi, F., Chiarugi, P. Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players. Biochim. Biophys. Acta 2013, 1836, 321–335.
105. Camorani, S., Hill, B.S., Fontanella, R., Greco, A., Gramanzini, M., Auletta, L., Gargiulo, S., Albanese, S., Lucarelli, E., Cerchia, L., et al. Inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an anti-PDGFRβ aptamer. Theranostic 2017, 7, 3595–3607.
106. Shipitsin, M., Campbell, L.L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11, 259–273.
107. Valenti, G., Quinn, H.M., Heynen, G.J.J.E., Lan, L., Holland, J.D., Vogel, R., Wulf-Goldenberg, A., Birchmeier, W. Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors. Cancer Res 2017, 77, 2134–2147.
108. Wyckoff, J., Wang, W., Lin, E.Y., Wang, Y., Pixley, F., Stanley, E.R., Graf, T., Pollard, J.W., Segall, J., Condeelis, J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64, 7022–7029.
109. Lu, H., Clauser, K.R., Tam, W.L., Fröse, J., Ye, X., Eaton, E.N., Reinhardt, F., Donnenberg, V.S., Bhargava, R., Carr, S.A., et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 2014, 16, 1105–1117.
110. Friedl, P., Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011, 147, 992–1009.
111. Scheel, C., Eaton, E.N., Li, S.H., Chaffer, C.L., Reinhardt, F., Kah, K.J., Bell, G., Guo, W., Rubin, J., Richardson, A.L., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145, 926–940.
112. Deryugina, E.I., Quigley, J.P. Cell surface remodeling by plasmin: A new function for an old enzyme. J. Biomed. Biotechnol. 2012, 2012, 564259.
113. Duffy, M.J., McGowan, P.M., Harbeck, N., Thomssen, C., Schmitt, M. uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014, 16, 428.
114. Harbeck, N., Kates, R.E., Look, M.P., Meijer-Van Gelder, M.E., Klijn, J.G., Krüger, A., Kiechle, M., Jänicke, F., Schmitt, M., Foekens, J.A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002, 62, 4617–4622.
115. De Cremoux, P., Grandin, L., Diéras, V., Savignoni, A., Degeorges, A., Salmon, R., Bollet, M.A., Reyal, F., Sigal-Zafrani, B., Vincent-Salomon, A., et al. Breast Cancer Study Group of the Institut Curie. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res. 2009, 29, 1475–1482.
116. Tang, L., Han, X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother. 2012, 67, 179–182.
117. Vella, L.J. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front. Oncol. 2014, 4, 361.
118. Simons, M., Raposo, G. Exosomes-Vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21, 575–581.
119. Luga, V., Zhang, L., Viloria-Petit, A.M., Ogunjimi, A.A., Inanlou, M.R., Chiu, E., Buchanan, M., Hosein, A.N., Basik, M., Wrana, J.L. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151, 1542–1556.
120. Lin, R., Wang, S., Zhao, R.C. Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol. Cell. Biochem. 2013, 383, 13–20.
121. Menck, K., Klemm, F., Gross, J.C., Pukrop, T., Wenzel, D., Binder, C. Induction and transport of Wnt 5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles. Oncotarget 2013, 4, 2057–2066.
122. Chen, Y., Zeng, C., Zhan, Y., Wang, H., Jiang, X., Li, W. Aberrant low expression of p85
123. Cho, J.A., Park, H., Lim, E.H., Lee, K.W. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int. J. Oncol. 2012, 40, 130–138.
124. King, H.W., Michael, M.Z., Gleadle, J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12, 421.
125. Fasanaro, P., D’Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M.C., Martelli, F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-A3. J. Biol. Chem. 2008, 283, 15878–15883.
126. Zhang, J., Ma, L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev. 2012, 31, 653–662.
127. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659.
128. Yang, M., Chen, J., Su, F., Yu, B., Su, F., Lin, L., Liu, Y., Huang, J.D., Song, E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10, 117.
129. Zhao, M., Ang, L., Huang, J., Wang, J. MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis. Tumour Biol. 2017, 39.
130. Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., Enzo, E., Guzzardo, V., Rondina, M., Spruce, T., et al. A microRNA targeting dicer for metastasis control. Cell 2010, 141, 1195–1207.
131. Zhang, H.F., Xu, L.Y., Li, E.M. A family of pleiotropically acting microRNAs in cancer progression, miR-200: Potential cancer therapeutic targets. Curr. Pharm. Des. 2014, 20, 1896–1903.
132. Pattabiraman, D.R., Bierie, B., Kober, K.I., Thiru, P., Krall, J.A., Zill, C., Reinhardt, F., Tam, W.L., Weinberg, R.A. Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science 2016, 351, aad3680.
133. Pattabiraman, D.R., Weinberg, R.A. Targeting the epithelial-to-mesenchymal transition: The case for differentiation-based therapy. Cold Spring Harb. Symp. Quant. Biol. 2016, 81, 11–19.
134. Pattabiraman, D., Ostendorp, J., Weinberg, R. Inducing a mesenchymal-to-epithelial transition for the differentiation therapy of aggressive breast carcinomas. In Proceedings of the EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies: From Cancer Biology to the Clinic, Florence, Italy, 24–27 June 2017.
135. Yoshida, T., Ozawa, Y., Kimura, T., Sato, Y., Kuznetsov, G., Xu, S., Uesugi, M., Agoulnik, S., Taylor, N., Funahashi, Y., et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 2014, 110, 1497–1505.
136. Lin, D., Kuang, G., Wan, J., Zhang, X., Li, H., Gong, X., Li, H. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol. Rep. 2017, 37, 1148–1158.
137. Huang, J., Yang, B., Xiang, T., Peng, W., Qiu, Z., Wan, J., Zhang, L., Li, H., Li, H., Ren, G. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway. Mol. Nutr. Food Res. 2015, 9, 1063–1075.
138. Li, H., Huang, J., Yang, B., Xiang, T., Yin, X., Peng, W., Cheng, W., Wan, J., Luo, F., Li, H., et al. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. Toxicol. Appl. Pharmacol. 2013, 272, 180–190.
139. Fan, J.X., Zheng, D.W., Rong, L., Zhu, J.Y., Hong, S., Li, C., Xu, Z.S., Cheng, S.X., Zhang, X.Z. Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis. Biomaterials 2017, 139, 116–126.
140. Kast, R.E., Skuli, N., Cos, S., Karpel-Massler, G., Shiozawa, Y., Goshen, R., Halatsch, M.E. The ABC7 regimen: A new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer 2017, 9, 495–514.
141. Moore, K.M., Thomas, G.J., Duffy, S.W., Warwick, J., Gabe, R., Chou, P., Ellis, I.O., Green, A.R., Haider, S., Brouilette, K., et al. Therapeutic targeting of integrin avβ6 in breast cancer. J. Natl. Cancer Inst. 2014, 106, dju169.
142. Gilboa-Geffen, A., Hamar, P., Le, M.T., Wheeler, L.A., Trifonova, R., Petrocca, F., Wittrup, A., Lieberman, J. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. Mol. Cancer Ther. 2015, 14, 2279–2291.
143. Sempere, L.F., Keto, J., Fabbri, M. Exosomal microRNAs in breast cancer towards diagnostic and therapeutic applications. Cancers 2017, 9, 71.
144. Ma, F., Li, W., Liu, C., Li, W., Yu, H., Lei, B., Ren, Y., Li, Z., Pang, D., Qian, C. MiR-23a promotes TGF-β1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/β-catenin signaling. Oncotarget 2017, 8, 69538–69550.
145. Wang, N., Wei, L., Huang, Y., Wu, Y., Su, M., Pang, X., Wang, N., Ji, F., Zhong, C., Chen, T., et al. miR520c blocks EMT progression of human breast cancer cells by repressing STAT3. Oncol. Rep. 2017, 37, 1537–1544.
146. Ma, L., Reinhard, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E.G., Teruya-Feldstein, J., Bell, G.W., Weinberg, R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28, 341–347.
147. Knezevic, J., Pfefferle, A.D., Petrovic, I., Greene, S.B., Perou, C.M., Rosen, J.M. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene 2015, 34, 5997–6006.
148. Bai, W.D., Ye, X.M., Zhang, M.Y., Zhu, H.Y., Xi, W.J., Huang, X., Zhao, J., Gu, B., Zheng, G.X., Yang, A.G., et al. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int. J. Cancer 2014, 135, 1356–1368.
149. O’Brien, K., Lowry, M.C., Corcoran, C., Martinez, V.G., Daly, M., Rani, S., Gallagher, W.M., Radomski, M.W., MacLeod, R.A., O’Driscoll, L. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015, 6, 32774–32789.
150. Hannafon, B.N., Carpenter, K.J., Berry, W.L., Janknecht, R., Dooley, W.C., Ding, W.Q. Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA). Mol. Cancer 2015, 14, 133.